Versum Materials — Proxy Contest (March 2019)
26 slides from Versum Materials's proxy contest presentation, Mar 14, 2019
Slide 1: Our Superior Proposal: Why Merck KGaA is the Right Owner of Versum
March 14, 2019 OUR SUPERIOR PROPOSAL WHY MERCK KGAA, DARMSTADT, GERMANY IS THE RIGHT OWNER OF VERSUM
Slide 2: Disclaimer
Disclaimer Publication of Merck KGaA, Darmstadt, Germany . In the United States and Canada the group of companies affiliated with Merck KGaA, Darmstadt, Germany operates under individual business names (EMD Serono, Millipore Sigma, EMD Performance Materials) . To reflect such fact and to avoid any m
Slide 3: Disclaimer: Cautionary Note Regarding Forward-Looking Statements
3 Disclaimer Cautionary Note Regarding Forward - Looking Statements and financial indicators This communication may include “forward - looking statements . ” Statements that include words such as “anticipate,” “expect,” “should,” “would,” “intend,” “plan,” “project,” “seek,” “believe,” “will,” and o
Slide 4: Disclaimer: Additional Important Information and Where to Find It
4 Disclaimer Additional Important Information and Where to Find It This communication does not constitute an offer to buy or solicitation of an offer to sell any securities . This communication relates to the proposal which Merck KGaA , Darmstadt, Germany has made for a business combination transact
Slide 5: Our superior proposal for Versum shareholders
Our superior proposal for Versum shareholders 5 Source: CapIQ . 1 As of January 25, 2019; 2 Entegris share price as at March 13, 2019, multiplied by 1.120 exchange ratio; 3 Refer to page 15 for further detail Our superior proposal • Superior to Entegris ’ proposal and • in the best interest of Versu
Slide 6: Significant discount to current trading
6 Significant discount to current trading Entegris’ deal is currently valued at a significant discount to Versum’s prevailing stock price Value proposition is inferior Analysis by Versum’s financial advisor, Lazard, clearly shows that our offer commands higher valuation than the Entegris merger cons
Slide 7: About us
| A Oi‘ = a8out us
Slide 8: Who we are: Sales by segment and region
8 Sales by segment Sales by region Total capex and R&D * ($bn) Sales development * ($bn) * Based on FY 2018 financials (shown in USD based on EUR/USD rate of 1.12). Healthcare: 42% Life Science: 42% Performance Materials: 16% Europe: 31% Asia - Pacific: 33% Middle East & Africa: 4% Latin America: 6%
Slide 9: Track record of successful acquisitions and financial flexibility
€ 20 € 30 € 40 € 50 € 60 € 70 € 80 € 90 € 100 € 110 € 120 2010 2012 2014 2016 2018 Merck KGaA Share Price ( € ) We have an outstanding track record of successful acquisitions and the financial flexibilities for further growth ▪ Strong track record of successful acquisitions, particularly in the U.S.
Slide 10: Why Versum and Merck KGaA fit so well together
10 Text slides and Textboxes Why Versum and Merck KGaA , Darmstadt, Germany fit so well together – creating a leading electronic materials player 1 2 3 4 Note: Financials shown in USD based on EUR/USD FX rate of 1.12 Create a leading player • Create one of the leading electronic materials players fo
Slide 11: Our proposal is superior
02 OUR PROPOSAL IS SUPERIOR
Slide 12: Versum shareholders should prefer the superior value and certainty of our Proposal
Versum shareholders should prefer the superior value and certainty of our Proposal 12 ▪ Highly certain, cash proposal of $48.00 per share ▪ ~52% premium over last unaffected Versum closing price ▪ 16% premium to Versum’s 2019 - high price prior to our bid, reflecting the value of Entegris offer ▪ Re
Slide 13: The market's reaction supports view that our proposal is superior
$48.80 $39.24 $48.00 $20 $30 $40 $50 1-Jan-2019 12-Jan-2019 23-Jan-2019 3-Feb-2019 14-Feb-2019 25-Feb-2019 8-Mar-2019 $ 27.72 Entegris Deal Value¹ Merck KGaA, Darmstadt, Germany Offer The market’s reaction supports view that our proposal is superior Source: Capital IQ, market data as of March 8, 201
Slide 14: Lazard's published analysis supports our proposal being superior
The published financial analysis of Lazard – Versum’s own financial advisor – supports our view that our Proposal is superior to the Entegris acquisition Our Proposal is superior to Lazard’s valuation of Versum on a standalone basis 1 … 14 … and when compared to Lazard’s DCF value of the merger cons
Slide 15: Versum valuation multiples versus precedent transactions
Source: Public filings, press releases. Note: Versum multiples based on FY 2018A EBITDA of $446m and net debt as of December 31, 2018 of $599m (incl. $20m underfunded pensions), plus $36m minority interest. Diluted Versum shares outstanding calculated using the treasury stock method resulting in sha
Slide 16: Concerns about the Versum/Entegris proposal
CONCERNS ABOUT THE VERSUM /ENTEGRIS PROPOSAL
Slide 17: Versum's process was flawed, rushed and pre-conceived
Versum’s process to date was flawed, rushed and pre - conceived – if not changed now, shareholders could miss out on our superior proposal Versum did not engage with us and is employing delay tactics The current deal is not a result of a rigorous assessment Entire process to date has been hurried an
Slide 18: Cost synergies increased to level inconsistent with Versum's cost base
9.6 % 15.2 % 26.7 % 39.4 % 42.7 % 52.3 % 87.2 % Platform Specialty / OM Group Elec. Chem. Platform Specialty / Alent Cabot Microelectronics / KMG Merck / AZ Electronic Materials Entegris / ATMI ENTG / VSM Synergy Estimate ENTG / VSM Synergy Estimate with "Newly Found" Synergies¹ 4.3 % 5.4 % 5.4 % 6.
Slide 19: Versum's newly found synergies are unsubstantiated, speculative and illusory
19 Versum’s newly found synergies are unsubstantiated, speculative and illusory Source: Public filings What this means Versum and Entegris are trying to salvage their deal by attempting to improve their value proposition This is further evidence of a poor process If the original process had been r
Slide 20: Versum stakeholders should be concerned
20 Versum stakeholders should be concerned Pro forma governance favors Entegris • Entegris will have the majority of the Board (5 out of 9 directors), including the Entegris CEO • Entegris CEO and CFO will be the surviving executive leadership team Aggressive adoption of poison pill • Versum failed
Slide 21: How shareholders can win
04 HOW SHAREHOLDERS CAN WIN
Slide 22: What should Versum shareholders do?
22 Our proposal is superior We are the right owners of this asset The transaction process has been flawed What should Versum shareholders do? Why Merck KGaA , Darmstadt, Germany is the right owner of Versum • Leading science and technology company, active in 3 areas: Healthcare, Life Science and Per
Slide 23: A compelling proposal for all stakeholders
23 A compelling proposal for all stakeholders Providing leading - edge technology backed by the capabilities, scale and quality of Merck KGaA, Darmstadt, Germany Truly global footprint and close proximity to customers worldwide Combines innovation strength to better serve our customers in a rapidly
Slide 24: Demand that Versum engage with us and vote the Green Proxy
If you support our superior proposal, demand that Versum engage with us, and, when available, vote the Green Proxy against the inferior Entegris acquisition Significant Premium 52% premium over Versum’s unaffected price, representing a total transaction value of $5.9bn All Cash Offer Our bid is not
Slide 25: Vote the GREEN proxy for our superior proposal
Vote the GREEN proxy for our superior proposal 25 DISCARD any proxy cards sent to you by Versum as they will count as votes against the value and certainty of the Merck KGaA, Darmstadt, Germany transaction If you have any questions, require assistance with voting your GREEN proxy card or need additi
Slide 26: Slide 26